Table 20.
Patient Characteristics and Clinical Data.
| Characteristic | Success n = 106 |
Failed n = 30 |
p-value |
|
| |||
| Age | 67.0 (17.4–97.7)1 | 74.3 (23.1–88.4) | 0.354 |
| Women | 64 (60.4%) | 14 (46.7%) | 0.180 |
| Diabetes | 18 (17%) | 8 (26.7%) | 0.234 |
| Previous MI | 24 (22.6%) | 7 (23.3%) | 0.936 |
| Recurrent UTI | 26 (24.5%) | 7 (23.3%) | 0.893 |
| Immunosuppressed | 21 (19.8%) | 11 (36.7%) | 0.055 |
| Chronic PPI1 | 50 (47.2%) | 19 (63.3%) | 0.118 |
| Post-FMT Abx3 | 16 (15.1%) | 7 (23.3%) | 0.288 |
| Chronic Statin2 | 35 (33%) | 14 (46.7%) | 0.169 |
| IBD | 13 (12.3%) | 2 (6.7%) | 0.388 |
| Charlson Index | 4 (0–11)1 | 5 (0–11) | 0.013 |
| COPD | 13 (12.3%) | 10 (33.3%) | 0.007 |
| Maximum WBC4 | 13.4 (4.7–45.4)1 | 21.1 (6.7–58.3) | <0.001 |
| Hospital-acquired | 36 (34%) | 21 (70%) | <0.001 |
| Inpatient Status | 19 (17.9%) | 21 (70%) | <0.001 |
| Refractory to Abx5 | 0 | 9 (30%) | <0.001 |
| Severe/complicated | 6 (5.7%) | 11 (36.7%) | <0.001 |
1Median (range); 2Use for >12 weeks before FMT; 3For reasons other than CDI; 4Maximum count during any recurrence; 5Complete non-responsiveness to antibiotics.